The year 2025 has begun robustly for Disc, as the company reports significant operational strides within its portfolio. Central to these advancements is the APOLLO trial for bitopertin targeting EPP, which has now commenced. Disc believes bitopertin could significantly impact patient lives, and expresses gratitude to the physician, advocate, and patient communities for their sustained interest and collaboration in this venture.
Furthermore, Disc acknowledges the proactive involvement of regulatory bodies. Recent discussions focused on CMC elements have aligned crucial components necessary for the planned NDA submission in the latter half of 2025. This timely regulatory engagement underscores the momentum behind Disc's efforts to bring bitopertin to market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Disc Medicine Inc (IRON, Financial) is $98.40 with a high estimate of $132.00 and a low estimate of $75.00. The average target implies an upside of 131.12% from the current price of $42.58. More detailed estimate data can be found on the Disc Medicine Inc (IRON) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Disc Medicine Inc's (IRON, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
